UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics

, and slightly raised its price target from $10.00 to $11.00. Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.” Amicus Therapeutics closed on Tuesday at $6.02.